Novel strategies against multidrug resistance mediated by p-glycoprotein
- S. Casco,
- Universidad Popular Autonoma de Puebla,
- Centro de investigación oncológica-UNE-UPAEP
Publication Information
Tipo di output
Lingua originale
EnglishPagine da-a (Numero di pagine)
Pagine 169-175 (7 pagine)Rivista (volume, numero edizione)
Drugs of the Future (Volume 41, Edizione 3)Attività cardine della pubblicazione
- Published - 01/03/2016
Stato pubblicazione
ISSN
0377-8282Publication IDs
- Scopus: 84973563166
Abstract
P-glycoprotein (P-gp) is an ATP-binding cassette (ABC) protein that mediates the ATP-dependent efflux of hydrophobic toxins. Physiologically, P-gp excretes endogenous metabolites and other xenotoxic substrates into the urine, bile and feces. P-gp is a multidrug resistance (MDR) pump, which exports chemotherapeutic agents from target cells to the extracellular space. P-gp is considered an adverse factor in the prognosis of hematological and solid tumors because efflux of chemotherapeutic drugs reduces their intracellular levels, requiring higher doses to produce an effect equivalent to that before the P-gp overexpression. Effective P-gp modulators must inhibit P-gp activity, avoiding pharmacological interactions and toxicity. Nanoparticle-based advanced delivery systems have been recently studied, showing that these novel strategies can overcome MDR in some cancers.
